May 02, 2011 08:52 ET

Equity Research on Salix Pharmaceuticals Ltd. and Mylan Inc. -- Generic Drugs Gaining Ground

NEW YORK, NY--(Marketwire - May 2, 2011) - has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drugs - Generic industry and are offering free analytical research on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Mylan Inc. (NASDAQ: MYL). Register with us today at to have free access to this research or speak to one of our pros at

The economic downturn has motivated consumers to try lowering spending in all facets of their lifestyles. This includes medicines where generic drugs offer a much less expensive alternative to brand name versions. Generic drugs have gained a great deal of popularity for this reason, providing relatively similar efficacy at less cost. Get instant analyses of Salix Pharmaceuticals Ltd. and Mylan Inc. from live, real-time experts standing by at There is no commitment to join. is the Ultimate Trading Environment for investors. If you are considering owning Salix Pharmaceuticals Ltd. and Mylan Inc. then you should sign up for a free membership and our complimentary reports today at Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.

Most pharmacies are now reporting that over 70% of their prescription and drug dispensation is in generics now that more options are available and physicians have begun to prescribe them more often.

Not surprisingly, this has created a major opportunity for companies that specialize in generic medications. One of the biggest generic drug-makers, Mylan Inc., currently has 165 generic applications in with the FDA, representing approximately $98.5 billion in sales annually. Mylan Inc. report is accessible for free by registering today at

While the European generic market is struggling somewhat lately, the slate of huge drugs coming off of patent protection means there is even more opportunity available for companies like Salix Pharmaceuticals if they can get FDA approval and begin selling their own generic versions. Salix Pharmaceuticals Ltd. report is accessible for free by registering today at

The two Drugs - Generic stocks research reports are available for free by signing up now on


Shine's Room Online is the brain child of David Shine, a 15 year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link

Contact Information